REALI pooled database, encompassing Gla-300 studies conducted in different European countries, is a platform to identify factors contributing to glycemic control in patients with uncontrolled T2D initiated on Gla-300. A stepwise multivariable regression analysis was performed on selected demographic and baseline characteristics associated with achieving HbA1c target <7.5% after 6 months of Gla-300 treatment from 8 studies (3 interventional and 5 observational). The criterion for consideration and inclusion in the model was p < 0.05. Among 2558 subjects included, 48.7% reached target HbA1C <7.5%, 56% were male and 37% were insulin naïve. Mean (SD) age was 64 (9.4) years and BMI was 32.2 (5.3) kg/m2. Mean (SD) baseline HbA1c was 8.5 (1) % and starting Gla-300 dose 0.29 (0.18) U/kg/day. The analyses identified baseline HbA1c as the major predictive factor associated with achievement of HbA1c target <7.5%, with a nonlinear relationship, and odds were higher in the lowest baseline HbA1c value (p<0.0001). Male gender (p=0.0014), being insulin naïve (p<0.0001), and lower Gla-300 starting dose (p=0.0015) were also identified as potential predictors for achieving HbA1c target <7.5%. These results can help clinicians to identify patients with T2D treated with Gla-300, who are likely to achieve target HbA1c <7.5%.

graphic
View largeDownload slide
Disclosure

N. Freemantle: Advisory Panel; Self; Sanofi. Research Support; Self; Akcea Therapeutics, Allergan, AstraZeneca, Ipsen Biopharmaceuticals, Inc., Sanofi, Takeda Pharmaceutical Company Limited. Speaker's Bureau; Self; Sanofi. G. Bigot: None. M. Bonnemaire: Employee; Self; Sanofi. D. Mauricio: Advisory Panel; Self; Merck Sharp & Dohme Corp., Sanofi. Speaker's Bureau; Self; Almirall, S.A., Boehringer Ingelheim International GmbH, Lilly Diabetes, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi, Urgo Medical. R.C. Bonadonna: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Sanofi-Aventis. Speaker's Bureau; Self; Eli Lilly and Company, Sanofi-Aventis. P. Gourdy: Advisory Panel; Self; AstraZeneca. Board Member; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi-Aventis, Servier. Speaker's Bureau; Self; Abbott, Amgen Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi-Aventis, Servier. A. Ciocca: Employee; Self; Sanofi. D. Müller-Wieland: Advisory Panel; Self; Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk Inc., Sanofi-Aventis Deutschland GmbH. Speaker's Bureau; Self; Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk Inc., Sanofi-Aventis Deutschland GmbH.

Funding

Sanofi

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.